DPDaniela Pineda-Cevallos

Daniela Pineda-Cevallos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Daniela Pineda-Cevallos has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Alba Moran-Alvarez

    Department of Morphology and Cell Biology, School of Medicine, University of Oviedo, Oviedo, Spain

    1 shared publication
  • Ana Álvarez

    Department of Organisms and Systems Biology and University Institute of Biotechnology of Asturias (IUBA), University of Oviedo, Asturias, Spain

    1 shared publication
  • Arindam Ghatak

    Molecular Systems Biology Lab (MOSYS), Department of Functional and Evolutionary Ecology University of Vienna Vienna Austria

    1 shared publication
  • Belen Garcia-Soler

    Department of Morphology and Cell Biology, School of Medicine, University of Oviedo, Oviedo, Spain

    1 shared publication
  • David Hevia

    Department of Morphology and Cell Biology, School of Medicine, University of Oviedo, Oviedo, Spain

    1 shared publication
  • Isabel Quiros-Gonzalez

    Department of Physics, University of Cambridge, Cambridge, United Kingdom

    1 shared publication

Latest Publications

  • Open Access

    TXNIP upregulation controls metabolism and cell cycle during androgen deprivation therapy in prostate cancer

    by Sergio Alcon-Rodriguez, Juan C. Mayo, Pedro Gonzalez-Menendez, Iván Fernandez-Vega, David Hevia, Sheila Fernandez-Vega, Alba Moran-Alvarez, Daniela Pineda-Cevallos, Miguel Alvarez-Mugica, Pablo Rodriguez-Gonzalez, et al.

    Thioredoxin-Interacting Protein (TXNIP) is an arrestin at the crossroad of redox and glycolytic metabolisms. Prostate cancer (PCa) exhibits a unique metabolic profile due to the glycolytic nature of healthy prostate tissue. We hypothesize that TXNIP plays a pivotal role in the progression of PCa to castration-resistant prostate cancer (CRPC), an incurable stage of the disease characterized by profound metabolic reprogramming and independence from androgens. Only a subset of patients progresses to CRPC, and current stratification tools lack robust biomarkers. TXNIP expression is directly suppressed by androgens and diminishes during tumor initiation and progression, as demonstrated in both human samples and a prostate adenocarcinoma mouse model (TRAMP). TXNIP regulates glucose metabolism by sequestering the glucose transporter GLUT1 away from the membrane, shifting metabolism from glycolysis to glutaminolysis. Nuclear-localized TXNIP induces cell cycle arrest through the upregulation of p27 kip1 which is downregulated together with TXNIP in CRPC. The response to androgen deprivation therapy (ADT) strongly depends on TXNIP expression. In the murine model, TXNIP levels were significantly higher in ADT responders compared to non-responders. Furthermore, TRAMP- Txnip − / − prostate tumors exhibited a poorer response to ADT, with increased Ki67 and enhanced viability. In clinical samples, all patients on relapse showed low levels of TXNIP and progressed to CRPC. Our findings identify TXNIP as a critical regulator of cell cycle and glucose metabolism in PCa and emphasize for the first time its essential role in mediating therapeutic responses to ADT.


  • Open Access

    Ferroptosis is the key cellular process mediating Bisphenol A responses in Chlamydomonas and a promising target for enhancing microalgae-based bioremediation

    by María Carbó, Palak Chaturvedi, Ana Álvarez, Daniela Pineda-Cevallos, Arindam Ghatak, Pablo Rodríguez González, María Jesús Cañal, Wolfram Weckwerth, Luis Valledor